Log inSign up
Bruce Booth
12.1K posts
Image
user avatar
Bruce Booth
@LifeSciVC
Early stage biotech VC. Recovering scientist. Opinions expressed are solely my own and do not express the views or opinions of Atlas Venture.
Cambridge, MA
atlasventure.com
Joined December 2010
736
Following
56.1K
Followers

New to X?

Sign up now to get your own personalized timeline!

Create account

By signing up, you agree to the Terms of Service and Privacy Policy, including Cookie Use.

Terms·Privacy·Cookies·Accessibility·Ads Info·© 2026 X Corp.
Don't miss what's happening
People on X are the first to know.
Log inSign up
  • user avatar
    Bruce Booth
    @LifeSciVC
    Sep 17, 2019
    Only in Cambridge: I’m stuck in traffic on the exit from the Pike and a biotech CEO pulls up next to me, rolls window down and says “Hey Bruce, we’ve got great NHP efficacy data... can’t wait to show you”... Made my commute far less painful! This ecosystem never ceases to amaze
  • user avatar
    Bruce Booth
    @LifeSciVC
    Feb 4, 2022
    Biotech is just so small. $FB lost $200B yesterday due to metaverse investing... which is more than the combined pre-money valuations of the 360+ biotech IPOs since 2015. Trying to make a virtual world vs trying to make real medicines. Both are challenging, it seems.
  • user avatar
    Bruce Booth
    @LifeSciVC
    May 6, 2021
    Waiving IP has consequences... slippery slope... now they say “do insulin next”? Let’s do PD1s after that because cancer is a global crisis... Then let’s do Alzheimer’s.. Oh wait, we have no drugs for AD yet... and nor will we if there are no patents or reward for innovating
  • user avatar
    Bruce Booth
    @LifeSciVC
    Mar 16, 2021
    Personal Reflection: Empathy In The Workplace Life isn't always easy, and many of us have a lot going on underneath the facade, but its the emotional connectedness with others that makes all the difference. To those that have been there for me, thx you
    lifescivc.com
    Personal Reflection: Empathy In The Workplace - LifeSciVC
    Just before I chaired a Board meeting last year, I spent a frustratingly painful hour going through many of the uncomfortable details of my divorce process and a set of emotional custody issues with...
  • user avatar
    Bruce Booth
    @LifeSciVC
    Mar 15, 2025
    One of the most compelling cold email VC pitches I've ever received... very hard to not feel a strong desire to invest in this startup and back this CEO... Can you imagine how fun Board meetings would be? Wow.
    Image
    73K
  • user avatar
    Bruce Booth
    @LifeSciVC
    Jan 14, 2019
    The Game Isn’t Worth The Candle: Reflections On The JPM Healthcare Conference. More concerned than ever about the value of the JPM week and what it says about our industry. lifescivc.com/2019/01/the-ga… #JPM19 #JPMHC19
    lifescivc.com
    The Game Isn’t Worth The Candle: Reflections On The JPM Healthcare Conference - LifeSciVC
    Another year, another JPM week. With a weekend to recuperate and reflect, I come away more concerned than ever about JPM and our industry. For context, by JPM I don’t mean the actual J.P. Morgan...
  • user avatar
    Bruce Booth
    @LifeSciVC
    Mar 24, 2020
    In mild COVID-19 patients, placebo was similarly effective to HCQ in viral clearance. Randomized open label clinical trial (NCT04261517): in 30 mild patients, 93% cleared virus w/in 7 days on placebo (vs 87% with HCQ). h/t Umer Raffat at EvercoreISI
  • user avatar
    Bruce Booth
    @LifeSciVC
    Apr 1, 2025
    FDA turmoil is creating huge uncertainty for biotech... so much institutional knowledge is being lost... and upheaval is never good for productivity. One of the most challenging aspects of this uncertainty is it's not clear (at least to me) what the direction of travel will be
    47K
  • user avatar
    Bruce Booth
    @LifeSciVC
    Nov 16, 2021
    Atlas Venture 2021 Year In Review Here's our "state of the industry" talk (that we just shared with our LP's at our Annual Meeting) exploring the macro issues & broader sector, diving into the biotech VC ecosystem, and providing a brief update on Atlas.
  • user avatar
    Bruce Booth
    @LifeSciVC
    Oct 14, 2025
    Twenty Years In Early Stage Biotech VC (Part 1) Here are some observations on the “Science” of startups from my vantage point as an early stage VC… · Science-first opportunism beats top-down strategy for deal selection · Don’t believe what you read in science papers at face
    user avatar
    Bruce Booth
    @LifeSciVC
    Oct 13, 2025
    Twenty years ago in mid-October 2005, I joined @atlasventure. Hard to believe - time flies. A big thank you to my partners JF Formela and Peter Barrett, who took a bet on me. Both have been great mentors, partners, and friends. Since 2005, I've worked with hundreds of
    lifescivc.com
    Twenty Years In Early Stage Biotech VC (Part 1): Science - LifeSciVC
    In the blink of an eye, twenty years have passed: in mid-October 2005, I joined Atlas Venture as a principal on the global life science team.  We closed Fund VII a few months after I joined; and,...
    88K
  • user avatar
    Bruce Booth
    @LifeSciVC
    Jul 1, 2024
    A Molecular Biologist’s Advice For Life. Having just turned 50, I’ve been reflecting on my first half-century… my passion for science as a lens for looking at the world has been a thread that has run throughout. Here are 12 pieces of advice for college & early career STEM
    61K
  • user avatar
    Bruce Booth
    @LifeSciVC
    May 14, 2021
    Surprising stat: >50% of biotech's that IPO'd between 2000-2013 have had at least one product approved. 8% of those IPOs actually got 2 products approved. (Thx to Josh Schimmer at Evercore ISI)
  • user avatar
    Bruce Booth
    @LifeSciVC
    Jan 14, 2025
    What a journey for Intracellular Therapies Inc ($ITCI) - acquired yesterday at the ripe age of 23 yrs old. Series A of $2.9M in 2002. Moshe Alafi, called one of the founders of biotech (whose VC firm backed Cetus, Amgen, ABI, others) was the lead of the A-round. Over next
    34K
  • user avatar
    Bruce Booth
    @LifeSciVC
    Nov 7, 2022
    Here’s the Atlas Venture 2022 Year In Review. This year, given the 2+ year rollercoaster in the mkts, we start with a deep dive into both the public and private #biotech capital markets, then to the industry overall, closing with an update on ⁦Atlas
Advertisement
Advertisement